@entity68 is implicated in the pathogenesis of @entity99 and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for @entity1561 ( @entity1561 ). We performed a prospective 6-month randomized, controlled trial examining the impact of phlebotomy on the background of lifestyle advice in @entity1 with @entity1561 . Primary endpoints were @entity1560 ( @entity1560 ; quantified by magnetic resonance imaging) and @entity99 (determined by @entity3929 aminotransaminase [ALT] and @entity2873 [ @entity2873 ]). Secondary endpoints included insulin resistance measured by the insulin sensitivity index (ISI) and homeostasis model of assessment (HOMA), and systemic lipid peroxidation determined by plasma @entity37336 levels. A total of 74 subjects were randomized (33 phlebotomy and 41 control). The phlebotomy group underwent a median (range) of 7 (1-19) venesection sessions and had a significantly greater reduction in ferritin levels over 6 months, compared to controls (-148        114 vs. -38        89 ng/mL; P   <   0.001). At 6 months, there was no difference between phlebotomy and control groups in @entity1560 (17.7% vs. 15.5%; P   =   0.4), serum ALT (36 vs. 46 IU/L; P   =   0.4), or @entity2873 levels (175 vs. 196 U/L; P   =   0.9). Similarly, there was no difference in end-of-study ISI (2.5 vs. 2.7; P   =   0.9), HOMA (3.2 vs. 3.2; P   =   0.6), or @entity37336 levels (1,332 vs. 1,190 pmmol/L; P   =   0.6) between phlebotomy and control groups. No differences in any endpoint were noted in @entity1 with @entity6737 at baseline. Among @entity1 undergoing phlebotomy, there was no correlation between number of phlebotomy sessions and change in @entity1560 , @entity99 , or IR from baseline to end of study. CONCLUSION: Reduction in ferritin by phlebotomy does not improve liver enzymes, hepatic fat, or IR in subjects with @entity1561 .

The impact of phlebotomy in XXXX : A prospective, randomized, controlled trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1560 :: ('MESH:D005234', 'Disease') :: ['hepatic steatosis', 'HS'] @entity37336 :: ('MESH:D028441', 'Chemical') :: ['F2-isoprostane'] @entity1561 :: ('MESH:D065626', 'Disease') :: ['NAFLD', 'nonalcoholic fatty liver disease'] @entity3929 :: ('D000409', 'Chemical') :: ['alanine'] @entity2873 :: ('3875', 'Gene') :: ['cytokeratin-18', 'CK-18'] @entity99 :: ('MESH:D056486', 'Disease') :: ['liver injury'] @entity6737 :: ('MESH:C538137', 'Disease') :: ['hyperferritinemia'] @entity68 :: ('MESH:D007501', 'Chemical') :: ['Iron']
@entity1561 :: (MESH:D065626,Disease) :: ['nonalcoholic fatty liver disease']
